Time flies with great content! Renew in to keep enjoying all our premium content.
Prime
Patients in Kenya to get HIV protection injection for Sh5,000
Lenacapavir for PrEP was approved by the US FDA in June, followed by a global recommendation from the World Health Organization in July and approval from the European Commission in August.
Millions of people at risk of HIV in 120 low- and middle-income countries, including Kenya, will have access to lenacapavir at $40 (approximately Sh5,170) per person per year, starting in 2027.
This follows a partnership between the Gates Foundation and the Indian pharmaceutical company Hetero Labs, which will manufacture a generic version of the original drug produced by Gilead Sciences.
